Transcode Therapeutics Inc (RNAZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Operating Expenses | 27,980 | 15,661 | 19,419 | 18,634 | 6,151 |
| Operating Income | -27,980 | -15,661 | -19,419 | -18,634 | -6,151 |
| Interest Expense | 7 | 27 | 56 | 32 | 95 |
| Other Income | -6,448 | -1,068 | 928 | 1,101 | -597 |
| Pre-tax Income | -34,435 | -16,755 | -18,546 | -17,565 | -6,843 |
| Income Tax | 226 | N/A | N/A | N/A | N/A |
| Net Income Continuous | -34,661 | -16,755 | -18,546 | -17,565 | -6,843 |
| Net Income | $-34,661 | $-16,755 | $-18,546 | $-17,565 | $-6,843 |
| EPS Basic Total Ops | -52.59 | -1,336.63 | -95,770.59 | -1,000,998.00 | -0.81 |
| EPS Basic Continuous Ops | -50.25 | -1,334.21 | -95,777.74 | -1,000,995.00 | -0.81 |
| EPS Diluted Total Ops | -52.59 | -1,336.63 | -95,770.59 | -1,000,998.00 | -0.81 |
| EPS Diluted Continuous Ops | -50.25 | -1,334.21 | -95,777.74 | -1,000,995.00 | -0.81 |
| EPS Diluted Before Non-Recurring Items | N/A | -1,320.45 | -95,783.52 | -998,419.12 | -599,051.38 |
| EBITDA(a) | $-27,866 | $-15,126 | $-18,902 | $-18,535 | $-6,109 |